8 results on '"Caballero Barrigón D"'
Search Results
2. Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation
- Author
-
M.V. Mateos, Cristina Calderón-Cabrera, Caballero Barrigón D, Teresa Caballero-Velázquez, San Miguel J, Jesús Martín, Francisco J. Márquez-Malaver, N. Puig, Lucía López-Corral, José A. Pérez-Simón, Clara M Rosso-Fernández, Estefania Perez-Lopez, Clara B. García-Calderón, and Ministerio de Sanidad y Política Social (España)
- Subjects
Melphalan ,medicine.medical_specialty ,Myeloma ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Phase I trials ,immune system diseases ,Internal medicine ,medicine ,Cumulative incidence ,Multiple myeloma ,Transplantation ,Bortezomib ,business.industry ,Hematology ,medicine.disease ,Tacrolimus ,Fludarabine ,surgical procedures, operative ,Graft-versus-host disease ,030220 oncology & carcinogenesis ,business ,030215 immunology ,medicine.drug - Abstract
This multicenter phase I trial was designed to evaluate the safety and efficacy of bortezomib (Bz) as part of both the conditioning regimen and the graft-versus-host disease (GvHD) prophylaxis. Patients received fludarabine, melphalan and Bz (days −9 and −2). GVHD prophylaxis consisted of Bz (days +1, +4, and +7), sirolimus (Siro) from day −5 and tacrolimus (Tk) from −3 (except the first five patients that did not receive Tk). Twenty-five patients with poor prognostic multiple myeloma were included. Eleven out of the 19 patients had high-risk features. Out of the 21 patients evaluable at day +100, 14 were in CR (67%) and 7 (33%) in PR. Cumulative incidence (CI) of nonrelapse mortality at 1 year was 24%. CI of grades 2–4 and 3–4 acute GvHD was 35% and 10%, respectively; CI of chronic GvHD was 35% and 55% at 1 and 2 years, respectively. Overall and event free survival at 2 years were 64% and 31%, respectively. Bz as part of the conditioning regimen and in the combination with Siro/tacrolimus for GvHD prophylaxis is safe and effective allowing an optimal disease control early after transplant and reducing the risk of GvHD., This trial was supported by Janssen and Celgene and the Ministerio de Sanidad y Política Social, convocatoria de concesión de ayudas para el fomento de la investigación clínica independiente 2010 (EC10–289); this study was partially supported by two grants from the Ministry of Health CIBER ONC, code CB16/12/00480. TCV was supported by a grant from Ministerio de Sanidad y Política Social (CM10/00161).
- Published
- 2019
3. Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation
- Author
-
Caballero-Velázquez, T., Calderón-Cabrera, C., López-Corral, L., Puig, N., Marquez-Malaver, F., Pérez-López, E., García-Calderón, C., Rosso-Fernández, C. M., Caballero Barrigón, D., Martín, J., Mateos, M. V., San Miguel, J., and Pérez-Simón, J. A.
- Abstract
This multicenter phase I trial was designed to evaluate the safety and efficacy of bortezomib (Bz) as part of both the conditioning regimen and the graft-versus-host disease (GvHD) prophylaxis. Patients received fludarabine, melphalan and Bz (days −9 and −2). GVHD prophylaxis consisted of Bz (days +1, +4, and +7), sirolimus (Siro) from day −5 and tacrolimus (Tk) from −3 (except the first five patients that did not receive Tk). Twenty-five patients with poor prognostic multiple myeloma were included. Eleven out of the 19 patients had high-risk features. Out of the 21 patients evaluable at day +100, 14 were in CR (67%) and 7 (33%) in PR. Cumulative incidence (CI) of nonrelapse mortality at 1 year was 24%. CI of grades 2–4 and 3–4 acute GvHD was 35% and 10%, respectively; CI of chronic GvHD was 35% and 55% at 1 and 2 years, respectively. Overall and event free survival at 2 years were 64% and 31%, respectively. Bz as part of the conditioning regimen and in the combination with Siro/tacrolimus for GvHD prophylaxis is safe and effective allowing an optimal disease control early after transplant and reducing the risk of GvHD.
- Published
- 2020
- Full Text
- View/download PDF
4. Potential protective effect of Helicobacter pylorion the development of gastrointestinal GvHD
- Author
-
Velasco-Guardado, A, Mora-Soler, A, López-Corral, L, López-Godino, O, Vázquez-López, L, Blanco-Muñez, O, Pérez-López, E, Rodríguez-Pérez, A, and Caballero-Barrigón, D
- Abstract
Previous reports ascribe a modulating capacity of the immune response to Helicobacter pylori(HP). Our hypothesis was to demonstrate in a prospective study that HP infection could have a protective effect against development of gastrointestinal GvHD in patients receiving allogeneic hematopoietic cell transplantation (HCT). Presence of HP before transplant was determined using C13urea breath test. Seventy-nine patients receiving an allogeneic HCT were included and 93.7% of them received PBSC; in 51.9%, the donor was unrelated. Acute gastrointestinal GvHD was diagnosed in 51.9% (n=41). In the multivariable analysis, HP infection was associated with a lower frequency of gastrointestinal GvHD (odds ratio (OR)=0.19 (95% confidence interval (CI): 0.05–0.67); in contrast, an unrelated donor was associated with a higher frequency of gastrointestinal GvHD (odds ratio=5.4 (95% confidence interval: 1.6–18.2). One year overall survival (OS) was 74%. In the multivariate Cox proportional-hazards regression analysis, stages 0–II gastrointestinal GvHD (hazards ratio (HR)=0.19), reduced intensity conditioning (HR=0.04) and tacrolimus-sirolimus GvHD prophylaxis (HR=0.06) were all associated with a better OS. In summary, HP infection could have a role in decreasing gastrointestinal GvHD in patients receiving allogeneic HCT from peripheral blood including related and unrelated donors.
- Published
- 2016
- Full Text
- View/download PDF
5. Prognosis of patients with acute lymphoblastic leukaemia relapsing after allogeneic stem cell transplantation.
- Author
-
Ferra Coll C, Morgades de la Fe M, Prieto García L, Vaz CP, Heras Fernando MI, Bailen Almorox R, Garcia-Cadenas I, Calabuig Muñoz M, Ripa TZ, Zanabili Al-Sibai J, Novoa S, Aguado B, Torrent Catarineu A, López-Godino O, Martino Bofarull R, Kwon M, Campos Júnior A, Caballero Barrigón D, and Ribera Santasusana JM
- Subjects
- Humans, Retrospective Studies, Transplantation, Homologous, Neoplasm Recurrence, Local, Stem Cell Transplantation, Prognosis, Acute Disease, Recurrence, Hematopoietic Stem Cell Transplantation adverse effects, Precursor Cell Lymphoblastic Leukemia-Lymphoma diagnosis, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma etiology
- Abstract
The outcomes of patients with acute lymphoblastic leukaemia (ALL) presenting relapse after allogeneic stem cell transplant (allo-SCT) are poor, with few data available in this setting., Objective and Methods: To evaluate the outcomes of patients with ALL presenting relapsed after allo-SCT, we performed a retrospective study including 132 from 11 centres in Spain., Results: Therapeutic strategies consisted of palliative treatment (n = 22), chemotherapy (n = 82), tyrosine kinase inhibitors (n = 26), immunotherapy with inotuzumab and/or blinatumumab (n = 19), donor lymphocyte infusions (n = 29 pts), second allo-SCT (n = 37) and CAR T therapy (n = 14). The probability of overall survival (OS) at 1 and 5 years after relapse was 44% (95% confidence interval [CI]: 36%; 52%) and 19% (95% CI: 11%; 27%). In the 37 patients undergoing a second allo-SCT, the 5-year estimated OS probability was 40% [22%; 58%]. Younger age, recent allo-SCT, late relapse, 1st complete remission at 1st allo-SCT and chronic graft-versus-host disease confirmed their positive impact on survival in the multivariable analysis., Conclusion: Despite the poor prognosis of patients with ALL presenting relapse after a first allo-SCT, some can be satisfactorily rescued and a second allo-SCT still remains a valid option for selected patients. Moreover, emerging therapies really might improve ALL patients outcome when relapsing after an allo-SCT., (© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
6. Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study.
- Author
-
Escamilla Gómez V, García-Gutiérrez V, López Corral L, García Cadenas I, Pérez Martínez A, Márquez Malaver FJ, Caballero-Velázquez T, González Sierra PA, Viguria Alegría MC, Parra Salinas IM, Calderón Cabrera C, González Vicent M, Rodríguez Torres N, Parody Porras R, Ferra Coll C, Orti G, Valcárcel Ferreiras D, De la Cámara LLanzá R, Molés P, Velázquez-Kennedy K, João Mende M, Caballero Barrigón D, Pérez E, Martino Bofarull R, Saavedra Gerosa S, Sierra J, Poch M, Zudaire Ripa MT, Díaz Pérez MA, Molina Angulo B, Sánchez Ortega I, Sanz Caballer J, Montoro Gómez J, Espigado Tocino I, and Pérez-Simón JA
- Subjects
- Acute Disease, Chronic Disease, Humans, Nitriles, Pyrazoles therapeutic use, Pyrimidines, Retrospective Studies, Graft vs Host Disease drug therapy, Hematopoietic Stem Cell Transplantation
- Abstract
Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. First-line treatment is based on the use of high doses of corticosteroids. Unfortunately, second-line treatment for both acute and chronic graft-versus-host disease, remains a challenge. Ruxolitinib has been shown as an effective and safe treatment option for these patients. Seventy-nine patients received ruxolitinib and were evaluated in this retrospective and multicenter study. Twenty-three patients received ruxolitinib for refractory acute graft-versus-host disease after a median of 3 (range 1-5) previous lines of therapy. Overall response rate was 69.5% (16/23) which was obtained after a median of 2 weeks of treatment, and 21.7% (5/23) reached complete remission. Fifty-six patients were evaluated for refractory chronic graft-versus-host disease. The median number of previous lines of therapy was 3 (range 1-10). Overall response rate was 57.1% (32/56) with 3.5% (2/56) obtaining complete remission after a median of 4 weeks. Tapering of corticosteroids was possible in both acute (17/23, 73%) and chronic graft-versus-host disease (32/56, 57.1%) groups. Overall survival was 47% (CI: 23-67%) at 6 months for patients with aGVHD (62 vs 28% in responders vs non-responders) and 81% (CI: 63-89%) at 1 year for patients with cGVHD (83 vs 76% in responders vs non-responders). Ruxolitinib in the real life setting is an effective and safe treatment option for GVHD, with an ORR of 69.5% and 57.1% for refractory acute and chronic graft-versus-host disease, respectively, in heavily pretreated patients.
- Published
- 2020
- Full Text
- View/download PDF
7. Endoscopic evaluation and histological findings in graft-versus-host disease.
- Author
-
Velasco-Guardado A, López-Corral L, Alvarez-Delgado A, Flores-Corral T, Geijo-Martínez F, Caballero-Barrigón D, and Rodríguez-Pérez A
- Subjects
- Adult, Aged, Biopsy, Female, Humans, Male, Middle Aged, Predictive Value of Tests, Retrospective Studies, Sensitivity and Specificity, Severity of Illness Index, Duodenum pathology, Esophagus pathology, Gastroscopy, Graft vs Host Disease pathology, Hematopoietic Stem Cell Transplantation, Stomach pathology
- Abstract
Background: the gastrointestinal (GI) tract is the major target site of the graft-versus-host disease (GVHD). Diagnosis is based on endoscopic and histological findings., Material and Methods: we performed a retrospective study from January 1st, 1990 to December 31st, 2008 on 338 upper gastrointestinal endoscopies (gastroscopies) performed to 197 patients that underwent an allogeneic transplant with clinical suspicion of GI-GVHD., Results: endoscopic findings to the diagnosis of GVHD have a sensitivity (S) of 34%, specificity levels (SP) of 65%, a positive predictive value (PPV) of 73% and a negative predictive value (NPV) of 48%. The histological study of the endoscopic biopsies has a global sensibility of 85.6% SP = 34.6% PPV = 64.2% and NPV = 63.7%. Histological grade was correlated with the clinical grade of acute GVHD (p = 0.018)., Conclusion: upper gastrointestinal endoscopy is useful for the diagnosis of GVHD, as it allows biopsies that can ultimately lead to the diagnosis, but with limited accuracy because the histological findings have low sensitivity and specificity, while the endoscopic findings are generally nonspecific.
- Published
- 2012
- Full Text
- View/download PDF
8. Helicobacter pylori infection and graft-versus-host disease.
- Author
-
Velasco Guardado A, López-Corral L, Pérez-Simón JA, Caballero-Velázquez T, Flores Corral T, Caballero Barrigón D, and Rodríguez Pérez A
- Subjects
- Anti-Bacterial Agents administration & dosage, Antineoplastic Agents administration & dosage, Biopsy, Female, Gastroscopy, Graft vs Host Disease diagnosis, Graft vs Host Disease drug therapy, Graft vs Host Disease physiopathology, Helicobacter Infections diagnosis, Helicobacter Infections drug therapy, Helicobacter Infections pathology, Helicobacter pylori growth & development, Hematologic Neoplasms physiopathology, Hematologic Neoplasms therapy, Humans, Immunosuppressive Agents administration & dosage, Male, Middle Aged, Retrospective Studies, Severity of Illness Index, Stem Cell Transplantation adverse effects, Stomach drug effects, Stomach pathology, Transplantation, Homologous, Graft vs Host Disease complications, Helicobacter Infections complications, Stomach microbiology
- Abstract
The gastrointestinal (GI) tract is the main target site of graft-versus-host disease (GVHD). Diagnosis is based on endoscopic and histological findings. Helicobacter pylori (HP) is a Gram-negative spiral bacterium linked to gastritis, peptic ulcer disease, gastric mucosa-associated lymphoid tissue lymphoma, and adenocarcinoma and is frequently observed on endoscopy in patients who have undergone transplantation. The role, if any, played by HP infection in the development of acute GVHD is unknown. We conducted a retrospective study between January 1, 1990, and December 31, 2008, of 338 upper GI endoscopies (gastroscopies) performed on patients who underwent allogeneic stem cell transplantation with clinical suspicion of GVHD (198 patients). Acute and chronic GVHD were confirmed from histological features in 97 patients (51.3%) and 68 patients (36%), respectively. HP infection was detected in 69 patients (35%) and had a negative modulating effect on the development of acute GVHD (relative risk [RR], 0.60; 95% confidence interval, 0.46-0.79; P = .001) and chronic GVHD (RR, 0.75; 95% confidence interval, 0.61-0.92; P = .016). Furthermore, the presence of HP was inversely correlated with the histological severity of GVHD (P = .003). Our findings suggest that infection with HP may have a negative modulating effect on GVHD., (Copyright © 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.